Intellia Therapeutics NTLA

HealthcareMarket cap $2B2 connections

Intellia's in-vivo CRISPR technology edits genes directly inside a patient's body after a single intravenous infusion. NTLA-2001 for ATTR amyloidosis showed 93% reduction in disease-causing protein in Phase 1 - among the most dramatic results ever seen in gene therapy. Intellia's approach could cure diseases that require lifelong drug treatment with a single injection.

Explore Intellia Therapeutics on the interactive map Relationship timeline Find a path to another company

Suppliers 1

Companies that sell to Intellia Therapeutics

AmazonConsumer & Retail · $2.0TIntellia drug development on AWS cloud

Partners 1

Strategic partnerships, joint products and alliances

CRISPR TherapeuticsHealthcare · $4BIntellia and CRISPR Therapeutics both in-vivo CRISPR

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Intellia Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=NTLA" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Intellia Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.